摘要
目的探讨醒脑静注射液联合吡贝地尔缓释片治疗急性脑梗死昏迷患者的临床效果。方法选取我院2017年6月至2018年10月收治的急性脑梗死昏迷患者120例,采用随机数字表法将其分为对照组与研究组,各60例。对照组于常规干预基础上给予吡贝地尔缓释片,研究组于对照组基础上给予醒脑静注射液,两组患者均治疗14d。比较两组治疗前、后的GCS、NIHSS评分、血清因子[干扰素-γ(IFN-γ)、肿瘤坏死因子-α(TNF-α)]水平及不良反应发生率。结果治疗后,两组患者的GCS较治疗前升高,NIHSS较治疗前降低,且研究组GCS及NIHSS评分均优于对照组(P<0.05)。治疗后,两组患者的IFN-γ及TNF-α水平均低于治疗前,且研究组低于对照组(P<0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论醒脑静注射液联合吡贝地尔缓释片治疗急性脑梗死昏迷患者的效果显著,可有效缓解患者的昏迷状态,恢复其神经功能,且不会增加不良反应,值得临床推广应用。
Objective To investigate the clinical effect of Xingnaojing injection combined with piribedil sustained-release tablets in the treatment of coma of acute cerebral infarction.Methods A total of 120 coma patients with acute cerebral infarction admitted in our hospital from June 2017 to October 2018 were divided into control group and study group according to the random number table method,with 60 cases in each group.On the basis of routine intervention,the control group was treated with piribedil sustained-release tablets,and the study group was treated with Xingnaojing injection on the basis of the control group,all patients were treated for 14 days.The scores of GCS NIHSS,levels of serum factor[interferon-γ(IFN-γ),tumor necrosis factor-α(TNF-α)]levels before and after treatment and the incidences of adverse reactions were compared between the two groups.Results After treatment,the GCS score of both groups was higher than that before treatment,the NIHSS scores were lower than those before treatment and those in the study group were better than the control group(P<0.05).After treatment,the levels of IFN-γand TNF-αin the two groups were lower than those before treatment,and those in the study group were lower than the control group(P<0.05).There was no significant difference in the total incidences of adverse reactions between the two groups(P>0.05).Conclusion Xingnaojing injection combined with piribedil sustained-release tablets has a significant clinical effect in the treatment of coma patients with acute cerebral infarction,it can effectively alleviate the coma state and restore the neurological function of patients,without increasing the risk of adverse reactions,which is worthy of clinical promotion and application.
作者
方晓康
FANG Xiao-kang(East Hospital of the First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710000,China)
出处
《临床医学研究与实践》
2019年第22期149-150,156,共3页
Clinical Research and Practice
关键词
急性脑梗死
昏迷
醒脑静注射液
吡贝地尔缓释片
acute cerebral infarction
coma
Xingnaojing injection
piribedil sustained-release tablets
